Local and Systemic Complications after Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Different Ocular Diseases: A Five-Year Retrospective Study-Reference-Cited by-同舟云学术

Local and Systemic Complications after Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Different Ocular Diseases: A Five-Year Retrospective Study

Published:2013-10-30 Issue:2 Volume:30 Page:129-135
ISSN:0882-0538
Container-title:Seminars in Ophthalmology
language:en
Short-container-title:Seminars in Ophthalmology

Author:

Nuzzi Raffaele,Tridico Federico

Publisher

Informa UK Limited

Subject

Ophthalmology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/08820538.2013.835833

Reference33 articles.

1. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial

2. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

3. Ranibizumab for Neovascular Age-Related Macular Degeneration

4. Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease

5. Ocular Complications After Anti–Vascular Endothelial Growth Factor Therapy in Medicare Patients With Age-Related Macular Degeneration

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data;European Journal of Ophthalmology;2024-03-11

2. Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration;International Journal of Nanomedicine;2024-02

3. Changes of Ocular Biometry and Intraocular Pressure in Patients Treated With Intravitreal Injection of Antivascular Endothelial Growth Factors;Malaysian Journal of Medicine and Health Sciences;2022-09-15

4. Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair;Cell Death & Disease;2022-08-29

5. Intravitreal dexamethasone: variation of surgical technique and prevention of ocular complications with ASOCT follow-up;Graefe's Archive for Clinical and Experimental Ophthalmology;2022-04-26